Trevena (TRVN)
(Delayed Data from OTC)
$2.34 USD
+0.21 (9.86%)
Updated Oct 16, 2024 03:46 PM ET
1-Strong Buy of 5 1
F Value B Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Trevena, Inc. [TRVN]
Reports for Purchase
Showing records 1 - 20 ( 115 total )
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
TRV045 Is Worth a Look Given a Differentiated Profile in the Blockbuster S1P Receptor Class
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Inpatient Hurdles Remain but New Real World Data Should Help; Reiterate Buy; Price Target Lowered to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Olinvyk Gets Needed Help with Vizient and Cognition Study; Reiterate Buy Though Lower Target to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Olinvyk Still Looking for Its Sea Legs; Reiterate Buy, Target Lowered to $3.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Adding Tiles to Olinvyk''s Data Mosaic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Royalty Financing Demonstrates Needed Patience Is Warranted for Olinvyk
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Rx for Portfolios, Part 3: Commercial Launches Worth Keeping an Eye On
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
TRV045 Cleared to Enter the Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Patience is Needed on Olinvyk Launch But New CCO Shows Trevena Is Making the Right Strategic Changes
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
TRV027 Shows Promising Efficacy in Small Hospitalized COVID-19 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Olinvyk Launch Curve Likely More Elongated Than Expected, But Good Things Come to Those Who Wait; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Progress in Formulary Wins as Leading Indicator of Olinvyk Uptake With New Studies Across Portfolio
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
TRV027 Selected for REMAP-CAP Study in COVID-19 Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Foundations in Place for Olinvyk Launch in a Pandemic Environment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
The Final Pieces of the Puzzle Fall Into Place as Olinvyk Is Poised for Commercial Launch; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Coverage at the 2020 H.C. Wainwright Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D